medigraphic.com
ISSN 2225-4676 (Digital)

2012, Número 1

<< Anterior Siguiente >>

Rev Cubana Neurol Neurocir 2012; 2 (1)


Diabetes mellitus y riesgo de ictus

Fernández CO, Buergo ZMÁ, López JM

Idioma: Español
Referencias bibliográficas: 45
Paginas: 56-60
Archivo PDF: 71.10 Kb.


RESUMEN

Objetivos: Revisar las evidencias disponibles que relacionan la diabetes mellitus con el riesgo de ocurrencia del ictus y el papel del control de la glicemia mediante diversas estrategias en la disminución del riesgo de ictus.
Desarrollo: La diabetes mellitus (DM) se asocia a un riesgo relativo de ictus isquémico entre 1,8 y 6; para el ictus hemorrágico esta asociación es controversial. Las mujeres diabéticas tipo 1 tienen mayor riesgo que aquellas con DM tipo 2. Además, la DM predice estadía hospitalaria prolongada, y mayor mortalidad y discapacidad en pacientes con ictus, los que sufren ictus fatales tienden a tener mayores niveles de HbA1c y de glicemia. Por otra parte, cerca del 9% de las recurrencias del ictus fueron atribuibles a la DM, por ello está incluida en las escalas pronosticas de recurrencia de la isquemia cerebral; además, es un factor de riesgo para la demencia post–ictus. Aunque en la DM tipo 1 el tratamiento intensivo de los niveles de glicemia se asoció a menores niveles de HbA1c y microalbuminuria, lo cual le confirió una reducción de eventos cardiovaculares en un 42%; en grandes ensayos clínicos con tratamiento intensivo para la DM tipo 2, la reducción de los niveles de glicemia y HbA1c, reducen las complicaciones microvasculares, pero no los eventos vasculares mayores. En cambio, el control más estricto de la tensión arterial, el uso de estatinas y una dieta tipo DASH, producen una reducción marcada del riesgo de ictus en diabéticos tipo 2.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007;6:182–7.

  2. Bonita R, Beaglehole R. Stroke prevention in poor countries. Time for action. Stroke. 2007;38:2871–2.

  3. World Heart Organization (WHO). The atlas of heart disease and stroke. WHO Geneva: Switzerland; 2004.

  4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:E442.

  5. Feigin VL, Lawes CMM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population based studies of incidence, prevalence, and case–fatality in the late 20th century. Lancet Neurol. 2003;2:43–53.

  6. Saposnik G, Del Brutto OH. Stroke in South America. A systematic review of incidence, prevalence, and stroke subtypes. Stroke. 2003;34:2103–8.

  7. Buergo Zuaznábar MA, Fernández concepción O, y col. Guías de Practicas clínicas par el ictus. ECIMED: Habana, 2008.

  8. Centers for Disease Control and Prevention (CDC). Prevalence of diabetes and impared fasting glucose in adults–United States, 1999–2000. MMWR Morb Mortal Wkly Rep. 2003 [citado 20.11.2009];52:833–7.

  9. WHO. Global strategy on diet, physical activity and health: diabetes. www.who.int/dietphysicalactivity/publications/facts/diabetes/ en/index.html

  10. Huang ES, Basy A, O’Grady M, Capretta JC. Projecting the future diabetes population size and related cost for the U.S. Diabetes Care. 209;32:2225–9.

  11. Leys D, Deplanque D, Mounier–Vehier C, Mackowiak– Cordoliani MA, Lucas C, Bordet R. Stroke prevention: management of modifiable vascular risk factors. J Neurol. 2002;249:507–17.

  12. Kissela BM, Lhoury J, Kleindorfer D, Woo D, Schneider A, Alwell K, et al. Epidemiology of Ischemic Stroke in Patients With Diabetes The Greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care. 2005;28:355–9.

  13. Megherbi SE, Milan C, Minier D, Couvreur G, Osseby GV, Tilling K, et al; European BIOMED Study of Stroke Care Group: Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke. 2003; 344:688–94.

  14. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(Suppl. 2):S54 –S64.

  15. Folsom AR, Rasmussen ML, Chambless LE, Howard G, Cooper LS, Schmidt MI, et al; For The Atherosclerosis Risk In Communities (ARIC) Study Investigators. Prospective Associations of Fasting Insulin, Body Fat Distribution and Diabetes With Risk of Ischemic Stroke. Diabetes Care. 1999;22:1077–83.

  16. Rodriguez BL, D’Agostino R, Abbott RD, Kagan A, Burchfiel CM, Yano K, et al. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: a comparison of incidence and risk factor effects. Stroke. 2002;33:230–6.

  17. Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risk of major cardiovascular diseases and death in the Asia–Pacific region. Diabetes Care. 2003;26:360–6.

  18. Janghorbani M, Hu FB, Willett WC, Li TY, Manson JE, Logroscino G, et al. Prospective Study of Type 1 and Type 2 Diabetes and Risk of Stroke Subtypes. The Nurses’ Health Study. Diabetes Care. 2007;30:1730–5.

  19. Spratt N, Wang Y, Levi C, Ng K, Evans M, Fisher J. A prospective study of predictors of prolonged hospital stay and disability after stroke. J Clin Neurosci. 2003;10:665–9.

  20. Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD; South London Stroke Register. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke. 2003;34:1457–63.

  21. Stevens RJ, Coleman Rl, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes. UKPDS 66. Diabetes Care. 2004;27:201–7.

  22. Nichols GA, Reinier K, Chugh SS. Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation. Diabetes Care 2009;32:1851–6.

  23. Yang X, Ko GTC, So WY, Ma RCW, Kong APS, Lam CWK. Additive Interaction of Hyperglycemia and Albuminuria on Risk of Ischemic Stroke in Type 2 Diabetes. Hong Kong Diabetes Registry. Diabetes Care. 2008;31:2294–300.

  24. Boden–Albala B, Cammack S, Chong J, Wang C, Wright C, Rundek T, et al. Diabetes, Fasting Glucose Levels, and Risk of Ischemic Stroke and Vascular Events Findings from the Northern Manhattan Study (NOMAS). Diabetes Care. 2008;31:1132–7.

  25. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

  26. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood–glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.

  27. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

  28. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.

  29. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD. Glucose Control and Vascular Complications in 2009;360:129–39.

  30. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta–analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–31.

  31. Yang X, Kong AP, So WY, Ma RC, Ho CS, Lam CW, et al. Effects of chronic hyperglycaemia on incident stroke in Hong Kong Chinese patients with type 2 diabetes. Diabetes Metab Res Rev. 2007;23:220–6.

  32. Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, Yoo SJ, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia. 2005;48:17–26.

  33. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long–term complications in insulin–dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.

  34. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905–12.

  35. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.

  36. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin–Converting– Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High–Risk Patients. N Engl J Med. 2000;342:145–53.

  37. Vijan S, Hayward RA. Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure. Goals, Choice of Agents, and Setting Priorities in Diabetes Care. Ann Intern Med. 2003;138:593–602.

  38. Patel A, Chalmers J, Neal B, Woodward M, Billot L, et al; ADVANCE Collaborative Group,. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590):829–40.

  39. Zannad F. Implications of the ADVANCE study for clinical practice. J Hypertens. 2008;26 Suppl 3:S31–4.

  40. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo–controlled trial. Lancet. 2004;364(9435):685–96.

  41. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol–lowering with simvastatin in 5963 people with diabetes: a randomised placebo– controlled trial. Lancet. 2003; 361(9374):2005–16.

  42. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol–lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta–analysis. Lancet. 2008;371(9607):117–25.

  43. Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER 3rd, Lin PH, et al; DASH Research Group.. Effects on blood lipids of a blood pressure–lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr. 2001;74:80–9.

  44. Liese AD, Nichols M, Sun X, D’agostino RB, Jr., Haffner SM. Adherence to the DASH Diet Is Inversely Associated With Incidence of Type 2 Diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes Care. 2009; 32:1434–6.

  45. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.




2020     |     www.medigraphic.com